NCT00189345View on ClinicalTrials.gov

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

October 31, 2005

Conditions
Ovarian CancerFallopian Tube NeoplasmsPeritoneal Neoplasms
Interventions
BIOLOGICAL

anti-EpCAM x anti-CD3 (removab)

Trial Locations (1)

35037

Dept. of Gynecology, University of Marburg, Marburg

All Listed Sponsors
lead

AGO Study Group

OTHER

NCT00189345 - Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients | Biotech Hunter | Biotech Hunter